Date: 2012-12-17
Type of information: Development agreement
Compound: animal health vaccine based on Imaxio’s immune-enhancing IMX313 technology
Company: Imaxio (France) Merial, a Sanofi company (France)
Therapeutic area: Veterinary medicine
Type agreement: development
licensing
Action mechanism:
Disease:
Details: Imaxio, a biopharmaceutical company specialized in the areas of vaccines and genomics, has signed an option for a licence agreement with Merial, the animal health division of Sanofi. The aim of this agreement is to develop an animal health vaccine based on Imaxio’s immune-enhancing IMX313 technology. The aim of IMX313, Imaxio’s proprietary technology for antigen re-engineering, is to significantly enhance the immune response and therefore, the efficacy of vaccines with which it is used.
Merial will conduct an internal review of the IMX313 technology for a period of 12 to 18 months and depending on results, will sign a licence agreement. Details of the vaccine candidate and the financial terms of the agreement have not been disclosed.
Financial terms:
Latest news:
